1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AstraZeneca's Imfinzi Steals March Into Untapped IO Lung Cancer Territory

 
• By Alexandra Shimmings

While most eyes were on AstraZeneca's keenly awaited MYSTIC lung cancer study of Imfinzi, its PACIFIC trial has ducked under the radar and hit investors with the nicest kind of surprise. The results could have wider implications for IO in earlier-stage cancers.

Radar
Pacific slipped under the radar • Source: Shutterstock

AstraZeneca PLC surprised the market with the unexpectedly early and positive results from its Phase III PACIFIC study of the newest PD-L1 blocker on the market, Imfinzi (durvalumab), in Stage III lung cancer. Its shares were up by more than 4.6% on the London Stock Exchange on the morning of May 12 as the added commercial opportunity sank in.

Not only do the results provide a fillip to AstraZeneca's immuno-oncology franchise by potentially securing first dibs on an NSCLC market segment that could have blockbuster potential in its own...

More from Clinical Trials

Stock Watch: How GSK’s Nucala Info Drip Helped Share Price

 
• By Andy Smith

The information flow in the months before the approval of GSK’s Nucala in COPD provides an interesting case study, and brings to mind the cautionary tale of Alnylam’s Onpattro.

ASCO: J&J Banks On T-Cell Engager’s Safety In Prostate Cancer

 
• By Andrew McConaghie

The company highlighted the KLK2-targeting agent’s safety at ASCO but it may have to rely on combinations to make pasritamig competitive.

ASCO: Regeneron Looks To Become Bigger Immuno-Oncology Player

 
• By Alaric DeArment

The drugmaker presented oral abstracts at the meeting for Libtayo in adjuvant cutaneous squamous-cell carcinoma and linvoseltamab in multiple myeloma.

ASCO: Lupin Presents Early Data On PRMT5 Inhibitor

 
• By Vibha Ravi

ASCO sees the debut of Lupin’s PRMT5 inhibitor candidate LRNP7457, currently in Phase I studies in India. While no drug with this mechanism of action has been approved anywhere so far, several candidates are in clinical trials.

More from R&D

Vera’s Atacicept Sets A New Efficacy Bar With Phase III Results In IgAN

 
• By Mandy Jackson

Vera is the first company to report Phase III data for a dual inhibitor of APRIL and BAFF in IgA nephropathy. Atacicept provided a 42% placebo-adjusted reduction in proteinuria.

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.